Translating the best science to improve human health is at our core. We focus both on trials that help define the role of specific molecular imaging agents, and trials using imaging to improve and optimize novel therapeutics.The imaging trials that we are leading use positron emission tomography or near infrared optical imaging. Four overarching themes are improved disease detection, margin delineation, in situ characterization across all disease sites and their evolution over time, and non-invasive assessment of response to targeted therapy. In each trial, we collaborate with disease specific experts to ensure the approach for each study directly addresses current major unmet clinical needs or helps to answer important questions regarding disease pathophysiology. As such we are in the process of clinical evaluation of a HER3 imaging agent and Granzyme B imaging agent that our team has developed. Additionally we have evaluated several investigational PET compounds in clinical trials that can help to tailor therapy and more accurately assess therapeutic outcomes than current technology.



  • Subcentimeter focal hepatic lesions.  At a prior outside hospital, the liver biopsy result was nondiagnostic, and the patient was referred to our institution for further management. Intraprocedural optical molecular images confirmed the accuracy of the biopsy needle placement, by measuring increased fluorescence, E, in the target lesion relative to, D, normal liver. Optical molecular images of core biopsy specimen show visualized areas of, F, focally increased ICG localization, G, in the core specimen (photograph). Final pathologic analysis of the core specimens revealed a nonneoplastic granulomatous process, with subsequent results of clinical and serologic evaluations most suggestive of sarcoidosis.


  • Patient fluorescence endoscopy. A benign polyp (hyperplastic, left) demonstrates no substantial ICG uptake over background (TBR 1.0), while a neoplastic one (tubular adenoma, right) does (TBR 1.7).



  • Representative maximum-intensity projection images of simultaneously acquired body MRI (A), 68Ga-DOTATOC PET (B), overlaid PET/MRI (C), volume of interest analysis (D) and overlaid volume of interest on representative PET image (E)



  • 18F-FES PET imaging of patients on GDC-0810 therapy demonstrate reduction of FES-avid metastases to background.